Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JRL-37
- Development stage
- Unknown
- Lead developer
- Jalon Therapeutics
- Modality
- Small Molecules, Peptides
01
Overview
JRL-37 is a synthetic peptide drug candidate developed by Jalon Therapeutics. It is currently in the discovery phase and is being investigated for the treatment of neoplasms (cancers). The precise mechanism of action, molecular targets, and additional pharmacological details have not been disclosed publicly. As of March 2025, there are no clinical trials or regulatory approvals reported for this compound[1][2][5].
Beyond the preview
Go deeper on JRL-37.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JRL-37.